Methods of treating hematologic cancers

Abstract

The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits.

What is claimed: 
     
         1 . A method of treating a hematologic cancer in a subject comprising the steps of:
 a. administering to the subject an effective amount Forodesine; and   b. administering to the subject an effective amount of an alkylating agent, wherein the administration of Forodesine and the alkylating agent results in a synergistic effect.   
     
     
         2 . The method of  claim 1 , wherein the alkylating agent is a mustard derivative, a nitrosourea derivative, a platinum compound, or an imidazole carboxamide compound. 
     
     
         3 . The method of  claim 1 , wherein the alkylating agent is Bendamustine. 
     
     
         4 . The method of  claim 1 , wherein Forodesine and the alkylating agent are administered concurrently. 
     
     
         5 . The method of  claim 1 , wherein Forodesine and the alkylating agent are administered sequentially. 
     
     
         6 . The method of  claim 1 , wherein the alkylating agent is administered one or more times prior to administration of Forodesine. 
     
     
         7 . The method of  claim 1 , wherein the hematologic cancer is non-Hodgkin's lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia. 
     
     
         8 . The method of  claim 1 , wherein the subject resistant to one or more chemotherapeutic agents. 
     
     
         9 . The method of  claim 8 , wherein the hematologic cancer is resistant to a purine nucleoside analogue. 
     
     
         10 . The method of  claim 8 , wherein the hematologic cancer is resistant to Fludarabine. 
     
     
         11 . The method of  claim 1 , wherein the hematologic cancer contains a p53 deletion. 
     
     
         12 . A pharmaceutical composition comprising Forodesine and an alkylating agent. 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the alkylating agent is a mustard derivative, a nitrosourea derivative, a platinum compound, or an imidazole carboxamide compound. 
     
     
         14 . The pharmaceutical composition of  claim 12 , wherein the alkylating agent is Bendamustine. 
     
     
         15 . A kit comprising Forodesine and an alkylating agent. 
     
     
         16 . The kit of  claim 15 , wherein the alkylating agent is a mustard derivative, a nitrosourea derivative, a platinum compound, or an imidazole carboxamide compound. 
     
     
         17 . The kit of  claim 15 , wherein the alkylating agent is Bendamustine. 
     
     
         18 . The kit of  claim 15 , further comprising a delivery system for at least one of Forodesine, and the alkylating agent. 
     
     
         19 . The kit of  claim 15 , further comprising instructions for treating a subject.